tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Biegler, 105 are a BUY (94.59%), 6 are a HOLD (5.41%).
Analyst Matthew Biegler, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 32.14% that have a potential upside of 39.52% achieved within 108 days.
Matthew Biegler’s has documented 206 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on OLMA, Olema Pharmaceuticals at 03-Sep-2025.
Analyst best performing recommendations are on CELU (CELULARITY).
The best stock recommendation documented was for VOR (VOR BIOPHARMA) at 3/21/2025. The price target of $8 was fulfilled within 182 days with a profit of $7.13 (819.54%) receiving and performance score of 45.03.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$4
$2.79 (230.58%)
$28
4 months 22 days ago
(13-May-2025)
1/2 (50%)
$3.04 (316.67%)
33
Hold
$3
$1.79 (147.93%)
6 months 26 days ago
(09-Mar-2025)
2/4 (50%)
$2.07 (222.58%)
111
Buy
$145
7 months ago
(05-Mar-2025)
0/1 (0%)
$52.99 (57.59%)
Hold
$5
$4 (400.00%)
$5
1 years 1 months 13 days ago
(22-Aug-2024)
1/2 (50%)
$1.23 (32.63%)
68
Hold
$5
$3.79 (313.22%)
$7
1 years 1 months 22 days ago
(13-Aug-2024)
7/12 (58.33%)
$1.73 (52.91%)
54
Which stock is Matthew Biegler is most bullish on?
Which stock is Matthew Biegler is most reserved on?
What Year was the first public recommendation made by Matthew Biegler?
